Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 220

1.

mTOR signaling pathway and mTOR inhibitors in cancer therapy.

Gomez-Pinillos A, Ferrari AC.

Hematol Oncol Clin North Am. 2012 Jun;26(3):483-505, vii. doi: 10.1016/j.hoc.2012.02.014. Epub 2012 Mar 31. Review.

PMID:
22520976
2.

[mTOR inhibitor].

Muro K.

Gan To Kagaku Ryoho. 2011 Jan;38(1):7-11. Japanese.

PMID:
21368454
3.

Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors.

Delbaldo C, Albert S, Dreyer C, Sablin MP, Serova M, Raymond E, Faivre S.

Target Oncol. 2011 Jun;6(2):119-24. doi: 10.1007/s11523-011-0177-6. Epub 2011 Apr 28. Review.

PMID:
21533544
4.

GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.

Wallin JJ, Edgar KA, Guan J, Berry M, Prior WW, Lee L, Lesnick JD, Lewis C, Nonomiya J, Pang J, Salphati L, Olivero AG, Sutherlin DP, O'Brien C, Spoerke JM, Patel S, Lensun L, Kassees R, Ross L, Lackner MR, Sampath D, Belvin M, Friedman LS.

Mol Cancer Ther. 2011 Dec;10(12):2426-36. doi: 10.1158/1535-7163.MCT-11-0446. Epub 2011 Oct 13.

5.

ATP-competitive inhibitors of mTOR: an update.

Schenone S, Brullo C, Musumeci F, Radi M, Botta M.

Curr Med Chem. 2011;18(20):2995-3014. Review.

PMID:
21651476
6.

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

Wu P, Hu YZ.

Curr Med Chem. 2010;17(35):4326-41. Review.

PMID:
20939811
7.

Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer.

Diaz-Padilla I, Duran I, Clarke BA, Oza AM.

Cancer Treat Rev. 2012 Oct;38(6):767-75. doi: 10.1016/j.ctrv.2012.02.001. Epub 2012 Feb 29. Review.

PMID:
22381585
8.

Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.

Nagata Y, Takahashi A, Ohnishi K, Ota I, Ohnishi T, Tojo T, Taniguchi S.

Int J Oncol. 2010 Oct;37(4):1001-10.

PMID:
20811722
9.

mTOR inhibitors: facing new challenges ahead.

Mavrommati I, Maffucci T.

Curr Med Chem. 2011;18(18):2743-62. Review.

PMID:
21649581
10.

Perspectives on mTOR inhibitors for castration-refractory prostate cancer.

Burgio SL, Fabbri F, Seymour IJ, Zoli W, Amadori D, De Giorgi U.

Curr Cancer Drug Targets. 2012 Oct;12(8):940-9. Review.

PMID:
22831278
11.

PI3K and mTOR signaling pathways in cancer: new data on targeted therapies.

Willems L, Tamburini J, Chapuis N, Lacombe C, Mayeux P, Bouscary D.

Curr Oncol Rep. 2012 Apr;14(2):129-38. doi: 10.1007/s11912-012-0227-y. Review.

PMID:
22350330
12.

Levels of p27 sensitize to dual PI3K/mTOR inhibition.

Lee M, Theodoropoulou M, Graw J, Roncaroli F, Zatelli MC, Pellegata NS.

Mol Cancer Ther. 2011 Aug;10(8):1450-9. doi: 10.1158/1535-7163.MCT-11-0188. Epub 2011 Jun 6.

13.

Targeting mTOR signaling pathway in ovarian cancer.

Mabuchi S, Hisamatsu T, Kimura T.

Curr Med Chem. 2011;18(19):2960-8. Review.

PMID:
21651485
14.

mTOR inhibitor for the treatment of hepatocellular carcinoma.

Kudo M.

Dig Dis. 2011;29(3):310-5. doi: 10.1159/000327565. Epub 2011 Aug 9. Review.

PMID:
21829022
15.

G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.

Gao N, Flynn DC, Zhang Z, Zhong XS, Walker V, Liu KJ, Shi X, Jiang BH.

Am J Physiol Cell Physiol. 2004 Aug;287(2):C281-91. Epub 2004 Mar 17.

16.

Dual inhibitors of PI3K/mTOR or mTOR-selective inhibitors: which way shall we go?

Sabbah DA, Brattain MG, Zhong H.

Curr Med Chem. 2011;18(36):5528-44. Review.

PMID:
22172063
17.

Multiple signal pathways in obesity-associated cancer.

Chen J.

Obes Rev. 2011 Dec;12(12):1063-70. doi: 10.1111/j.1467-789X.2011.00917.x. Epub 2011 Aug 22. Review.

PMID:
22093240
18.

mTOR kinase inhibitors as a treatment strategy in hematological malignancies.

Grzybowska-Izydorczyk O, Smolewski P.

Future Med Chem. 2012 Mar;4(4):487-504. doi: 10.4155/fmc.12.14. Review.

PMID:
22416776
19.

Inhibition of the mTOR/p70S6K pathway is not involved in the insulin-sensitizing effect of AMPK on cardiac glucose uptake.

Ginion A, Auquier J, Benton CR, Mouton C, Vanoverschelde JL, Hue L, Horman S, Beauloye C, Bertrand L.

Am J Physiol Heart Circ Physiol. 2011 Aug;301(2):H469-77. doi: 10.1152/ajpheart.00986.2010. Epub 2011 May 20.

20.

Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.

Svejda B, Kidd M, Kazberouk A, Lawrence B, Pfragner R, Modlin IM.

Cancer. 2011 Sep 15;117(18):4141-54. doi: 10.1002/cncr.26011. Epub 2011 Mar 8.

Items per page

Supplemental Content

Write to the Help Desk